10-K: LivaNova Reports $242M Net Loss in 2025 Amidst SNIA Liability

LivaNova PLC reported a significant net loss of $242.5 million for 2025, primarily driven by a substantial SNIA environmental liability, despite strong revenue growth in its core Cardiopulmonary and Neuromodulation segments.

Summary

• LivaNova PLC reported a net loss of $242.5 million for the year ended December 31, 2025, a significant decline from a net income of $63.2 million in 2024.
• Net revenue increased by 10.7% to $1,388.1 million in 2025, up from $1,253.4 million in 2024.
• The Cardiopulmonary segment's net revenue grew by 14.9% to $785.4 million, with segment income increasing by 40.9% to $108.3 million.
• The Neuromodulation segment's net revenue increased by 7.0% to $592.8 million, with segment income rising by 10.3% to $215.5 million.
• A major factor contributing to the net loss was a $365.6 million SNIA environmental liability expense recorded in 2025, following a decision by the Italian Supreme Court.
• The company incurred $1.5 million in direct costs related to a November 2023 cybersecurity incident in 2025, bringing the total direct costs to $13.1 million since the incident.
• LivaNova received $1.7 million in direct cost reimbursements and $0.6 million in business interruption reimbursements from insurance in 2025, totaling $10.7 million in reimbursements since the incident.
• Research and Development (R&D) expenses decreased as a percentage of net revenue to 13.4% in 2025, primarily due to an $18.9 million reduction in costs for the DTD program, partially offset by an $11.2 million increase for the aura6000 System development.
• The OSPREY clinical trial for the aura6000 System in obstructive sleep apnea (OSA) met its primary endpoints for efficacy and safety in 2024.
• LivaNova completed the CORE-VNS study for drug-resistant epilepsy (DRE) in June 2025, reporting 36-month data for pediatric and adult patients.
• The company initiated a process with CMS in June 2025 to seek reconsideration of national Medicare coverage for VNS Therapy in unipolar patients with treatment-resistant depression (TRD).
• Long-term debt was significantly reduced, with $280.9 million repaid in 2025, and an additional $97.7 million early repayment made on January 8, 2026, fully settling the Term Facilities.
• Cash and cash equivalents increased to $635.6 million as of December 31, 2025, from $428.9 million in 2024.
• The company's effective income tax rate was (9.8%) in 2025, compared to 28.4% in 2024, influenced by the SNIA environmental liability and valuation allowance changes.
• LivaNova had approximately 3,300 employees worldwide as of December 31, 2025, across 34 countries.
• The company continues to sell medical devices to distributors and non-governmental organizations in Iran, generating $10.9 million in gross revenues and $5.8 million in net profits from these activities in 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with a moderately negative sentiment. While operational segments show healthy revenue and income growth, the substantial one-time SNIA environmental liability resulted in a significant net loss, overshadowing positive business performance and introducing considerable financial uncertainty.

Positives

• Net revenue increased by 10.7% to $1,388.1 million in 2025, demonstrating strong top-line growth.
• Cardiopulmonary segment revenue grew by 14.9% to $785.4 million, driven by strong consumables demand and Essenz Perfusion System sales across all regions.
• Cardiopulmonary segment income increased significantly by 40.9% to $108.3 million, partly due to decreased litigation provision related to the 3T Heater-Cooler device.
• Neuromodulation segment revenue increased by 7.0% to $592.8 million, with growth across all regions.
• Neuromodulation segment income rose by 10.3% to $215.5 million, benefiting from increased revenue and reduced R&D costs for the DTD program.
• The OSPREY clinical trial for the aura6000 System in OSA successfully met its primary efficacy and safety endpoints, indicating potential for future product expansion.
• The CORE-VNS study for DRE was completed, with 36-month data published showing reductions in generalized tonic-clonic seizure frequency.
• Significant debt reduction occurred in 2025, with $280.9 million in long-term debt repaid, and the Term Facilities fully settled with an additional $97.7 million repayment in January 2026.
• Cash and cash equivalents increased to $635.6 million by year-end 2025, enhancing liquidity.
• The Office for Civil Rights formally closed its investigation into the November 2023 cybersecurity incident without civil monetary penalties or a corrective action plan, mitigating regulatory risk.
• The company successfully settled 2015-2018 Italian MedTech payback obligations for 25% of the originally requested amounts, reversing a $3.8 million reserve.

Negatives

• LivaNova reported a net loss of $242.5 million in 2025, a substantial reversal from net income in prior years.
• A significant SNIA environmental liability expense of $365.6 million was recorded in 2025 due to an Italian Supreme Court decision, impacting profitability.
• Cost of sales as a percentage of net revenue increased to 32.3% in 2025, up 0.4 percentage points from 2024, primarily due to unfavorable product mix.
• The company continues to incur direct costs related to the November 2023 cybersecurity incident, with $1.5 million in 2025, and may incur additional future costs.
• Insurance coverage for the cybersecurity incident may be insufficient to cover all costs and business interruption losses.
• The preliminary results for the unipolar depression cohort in the RECOVER clinical study did not meet their primary endpoint, potentially affecting future VNS Therapy coverage for TRD.
• The Italian Supreme Court determined LivaNova is jointly and severally liable for SNIA's environmental liabilities, up to an estimated 572.1 million euros ($671.1 million as of December 31, 2025), creating a substantial current liability.
• The company is involved in ongoing product liability litigation related to its 3T Heater-Cooler device, with approximately 65 filed and unfiled claims worldwide, and has self-insured a significant portion of these risks.
• The Italian MedTech payback measure continues to pose a potential liability, with a $12.8 million reserve for 2019 to the present.

Risks

• Volatility in the global market and worldwide economic conditions, including inflation, geopolitical instability, and fluctuating interest and exchange rates.
• Adverse changes in export and import costs, trade restrictions, global tariffs, and economic sanctions, including those affecting business dealings in Iran and Russia.
• Supply chain pressures, supplier shortages, and interruptions of components (e.g., fiber for oxygenators, rare earth magnets for heart-lung machines) could disrupt manufacturing and ability to meet demand.
• Failure to protect, maintain, or upgrade IT systems or products, or safeguard against cybersecurity incidents, service disruptions, or data corruption, including the increasing sophistication of cyber threats and potential use of AI in attacks.
• Costs of complying with privacy and security of personal information requirements and laws (e.g., HIPAA, HITECH, CCPA, GDPR), and potential liability from non-compliance or data breaches.
• Intense competition in the global medical device market from large manufacturers, specialized product providers, alternative medical therapies, pharmaceuticals, and surgical interventions.
• Failure to develop new and enhanced products and services on a timely basis, or to effectively integrate advanced software and AI capabilities, could lead to obsolescence and loss of competitive advantage.
• Risks and challenges associated with the incorporation and use of AI technologies, including flaws, breaches, malfunctions, legal challenges, and evolving regulatory landscapes.
• Failure of investments, alliances, acquisitions, or divestitures to achieve expected returns, or to successfully integrate acquired businesses, leading to unforeseen costs or diversion of management attention.
• Failure to maintain appropriate working relationships with healthcare professionals, which are crucial for product development and marketing.
• Quality issues with processes, products, and services could harm reputation, competitive advantage, revenue, and market share, potentially leading to recalls or enforcement actions.
• Failure to comply with U.S. and international product-related regulatory requirements (e.g., FDA 510(k) clearance, PMA, EU MDR), leading to restrictions, delays, or withdrawal of products.
• Inability to retain talent, maintain an effective succession plan, and successfully negotiate with local works councils, impacting operational flexibility and business continuity.
• Global healthcare policy changes, including cost containment initiatives, price regulation, and changes in reimbursement policies, could restrict access and pricing for LivaNova's products.
• Failure to comply with rules relating to reimbursement of healthcare goods and services, healthcare fraud and abuse, false claims, and anti-bribery laws (FCPA, UK Bribery Act), leading to penalties and reputational damage.
• The unfavorable impact of pending or existing climate change, including physical impacts of natural disasters and transitional risks like changing customer behaviors and increased input costs.
• Impairments of intangible assets, goodwill, and other long-lived assets due to negative industry trends, business disruptions, or market capitalization declines.
• Public health crises could decrease demand or increase volatility for products, impacting business and financial condition.
• Shareholder activism and increased investor engagement could divert management attention, disrupt operations, and adversely affect business and share price.
• Exposure to product liability claims, particularly related to the 3T Heater-Cooler device, with potential for significant monetary damages and reputational harm, and self-insurance for a significant portion of these risks.
• Heightened scrutiny on sustainability issues, including environmental and sustainability laws and regulations (e.g., EU CSRD), and the risk of environmental liabilities, violations, and litigation (e.g., Saluggia site, SNIA environmental litigation).
• Dependence on patent and other proprietary rights, with risks of infringement, misappropriation, challenges to validity, and difficulties in enforcing rights in certain jurisdictions (e.g., China).
• Inadequate funding for U.S. federal government agencies and government shutdowns could negatively affect product approvals, coverage decisions, and revenue from federal healthcare programs.
• Risks related to indebtedness, including insufficient cash flow to make payments or refinance, and the conditional conversion feature of the 2029 Notes affecting liquidity.
• Volatility in reported interest expense and financial results due to accounting for conversion features and capped calls as derivative instruments.
• Counterparty risk with respect to the 2029 Capped Calls, as LivaNova's exposure is unsecured.
• Being incorporated in England and Wales, which may afford less protection to shareholders than U.S. laws, and potential difficulties in enforcing U.S. court judgments.
• Changes in tax laws or exposure to additional income tax liabilities, including the OECD's Pillar Two global minimum tax rules and the U.S. OBBBA, could result in a higher effective tax rate.
• Certain capital structure decisions require shareholder approval under English law, potentially limiting flexibility in managing capital structure or granting equity awards.
• Transfers of LivaNova's shares, other than through DTC, may be subject to UK Stamp Duty or SDRT, potentially affecting trading price.
• If DTC determines LivaNova's shares are not eligible for continued deposit and clearance, trading could be disrupted and share price adversely affected.

Future Outlook

LivaNova anticipates continued monitoring of legislative developments and related guidance regarding Pillar Two and the OBBBA, which may impact its operations and effective tax rate. The company expects minimal residual activities and expenses from the 2024 Restructuring Plan. LivaNova believes its current liquidity sources will be sufficient to fund operations, capital expenditures, and debt service for the next twelve months. The company intends to continue its business in Iran, believing its activities comply with applicable laws. LivaNova also expects to make contributions of $0.1 million to its U.S. pension plan for the year ending December 31, 2026.

Management Comments

• "LivaNova's mission to create ingenious medical solutions that ignite patient turnarounds."
• "The Company continues to monitor broader economic developments — including inflation, tariffs, and increases in the cost of raw materials, components, labor, and transportation — which may affect production costs and customer pricing behavior."
• "While these dynamics place continued pressure on pricing, the Company employs a multifactorial approach to price setting to reflect the value delivered by its specialized products, while also providing customers with opportunities for cost efficiencies."
• "The Company believes that its accruals reflect the probable outcome of known contingencies."
• "Based on LivaNova's current business plan, the Company believes that its sources of liquidity... will be sufficient to fund its uses of liquidity... over the twelve-month period beginning from the issuance date of this Report."
• "LivaNova encourages its employees to act by LivaNova's four human imperatives of empowered accountability, constructive collaboration, curious mindset, and thoughtful humility."
• "The Company is committed to maintaining a workplace free from discrimination, bullying, intimidation, and harassment."

Industry Context

StockSavvy.ai notes that LivaNova operates in a highly competitive global medical device market characterized by rapid technological advances and scientific discoveries. The company's focus on R&D, including AI integration and software advancements, is critical for maintaining market leadership against competitors like Terumo Medical Corporation, Maquet Medical Systems, Medtronic plc, Haemonetics Corporation, Spectrum Medical Limited, and NeuroPace, Inc. The industry faces increasing pressure from global healthcare policy changes, cost containment initiatives, and evolving regulatory requirements (e.g., EU MDR), which necessitate continuous adaptation in pricing strategies and product development. The successful completion of clinical trials for new therapies like the aura6000 System for OSA positions LivaNova to potentially expand its market share in neuromodulation, while ongoing efforts to secure broader reimbursement for VNS Therapy in TRD are crucial for patient access and revenue growth in a challenging reimbursement landscape.

Comparison to Industry Standards

• LivaNova's Cardiopulmonary segment's 14.9% revenue growth in 2025 suggests strong performance relative to a mature market, potentially outperforming some peers in specific product categories like heart-lung machines and oxygenators, where innovation (e.g., Essenz Perfusion System) can drive adoption.
• The Neuromodulation segment's 7.0% revenue growth is solid, especially given the challenges in securing broad reimbursement for VNS Therapy in TRD. This growth indicates effective market penetration in DRE and anticipation for new therapies like the aura6000 System for OSA.
• The successful completion of the OSPREY clinical trial for the aura6000 System for OSA positions LivaNova to compete more directly with companies like Inspire Medical Systems, Inc. (INSP), which has a leading hypoglossal nerve stimulation device for OSA. The PolySync advanced titration algorithm could offer a competitive differentiation.
• The CORE-VNS study for DRE, evaluating real-world evidence from over 800 individuals, aligns with industry trends towards evidence-based medicine and post-market surveillance, similar to studies conducted by epilepsy device competitors like NeuroPace, Inc. (NPCE) for its RNS System.
• The significant net loss due to the SNIA environmental liability is a company-specific event and not indicative of broader industry financial health. However, it highlights the long-tail legal and environmental risks that can impact medical technology companies with historical operations or acquisitions.
• LivaNova's R&D investment, while decreasing as a percentage of revenue, is still substantial, reflecting the high capital intensity of developing and improving medical devices. The shift in R&D focus from DTD to OSA development indicates strategic resource allocation in response to clinical trial outcomes and market opportunities, a common practice among MedTech innovators.

Management Changes

Corporate Governance

Legal Proceedings

• SNIA Environmental Litigation: The Italian Supreme Court ruled on March 14, 2025, that LivaNova can be held jointly and severally liable for SNIA's environmental liabilities up to the fair value of net worth received by Sorin in 2004 (estimated 572.1 million euros or $671.1 million as of December 31, 2025). The case was referred back to the Court of Appeal to implement decisions on costs and damages. A current liability of $396.2 million was recorded as of December 31, 2025. A hearing is scheduled for June 24, 2026, to discuss a possible out-of-court resolution.
• Product Liability Litigation (3T Heater-Cooler device): LivaNova is involved in approximately 65 filed and unfiled claims worldwide. An additional liability of $4.7 million was recorded in 2025, bringing the total provision to $15.6 million as of December 31, 2025. Claims generally seek damages based on strict liability, negligence, breach of warranties, and other theories.
• Italian MedTech Payback Measure: The Constitutional Court determined in July 2024 that the payback law is compliant. In September 2025, LivaNova settled its 2015-2018 payment obligations for 3.5 million euros ($4.1 million), reversing a $3.8 million reserve. A reserve of $12.8 million remains for the years 2019 to the present.
• Cyber Litigation: Following the November 2023 cybersecurity incident, LivaNova USA was named in six putative class action lawsuits. A class action settlement of $1.2 million was accrued in Q3 2024 and approved on April 4, 2025. The HHS Office for Civil Rights closed its investigation into the incident on December 3, 2025, without civil monetary penalties or a corrective action plan.

Stakeholder Impact

• Shareholders: The significant net loss due to the SNIA environmental liability will negatively impact shareholder value and earnings per share. However, strong operational growth in core segments and debt reduction may provide some long-term confidence. The potential for future capital raises and the exclusion of pre-emption rights could lead to dilution.
• Employees: The 2024 Restructuring Plan involved winding down the ACS segment, which likely impacted employees in that area. The approval of new incentive plans (2025 Director Incentive Plan, Second A&R 2022 Plan) aims to attract and retain talent. The company emphasizes an inclusive culture and professional development.
• Customers: Product quality issues (e.g., 3T Heater-Cooler litigation) and potential supply chain disruptions could affect customer trust and product availability. Successful clinical trials (OSPREY) and efforts to expand reimbursement (VNS Therapy for TRD) could lead to new and improved treatment options.
• Creditors: The substantial debt repayment in 2025 and early settlement of Term Facilities in January 2026 significantly reduce the company's leverage and improve its credit profile, benefiting creditors.
• Regulatory Authorities: Ongoing compliance with complex regulations (FDA, EU MDR, anti-bribery laws, data privacy) is critical. The closure of the cybersecurity investigation without penalties is positive, but environmental liabilities (SNIA, Saluggia) remain a focus.

Next Steps

• Continue to monitor legislative developments and related guidance regarding Pillar Two and the OBBBA.
• Court of Appeal hearing scheduled for June 24, 2026, for SNIA litigation parties to discuss a possible out-of-court resolution.
• Seek reconsideration of national Medicare coverage for VNS Therapy in unipolar patients with TRD with CMS.
• Make contributions of $0.1 million to the U.S. pension plan for the year ending December 31, 2026.
• Achieve MDR certifications by December 2027 or December 2028, based on device risk classification.
• File the definitive 2026 Proxy Statement for the 2026 Annual General Meeting of Shareholders within 120 days of December 31, 2025.

Key Dates

Recommendation

LivaNova's core business segments (Cardiopulmonary and Neuromodulation) demonstrated solid revenue and income growth in 2025, indicating underlying operational strength and market demand for its products. The successful OSPREY clinical trial and debt reduction are also positive developments. However, the substantial one-time SNIA environmental liability, resulting in a significant net loss, introduces considerable financial uncertainty and will likely weigh on investor sentiment. While the liability is now recognized, the ongoing legal process and potential for further costs, coupled with other litigation and regulatory risks, suggest a 'hold' recommendation. Investors should monitor the resolution of the SNIA litigation and the company's ability to leverage its operational growth to absorb these one-time charges and improve future profitability.

Keywords

Medical Technology, Cardiopulmonary, Neuromodulation, VNS Therapy, Drug-Resistant Epilepsy, Treatment-Resistant Depression, Obstructive Sleep Apnea, SEC Filing, 10-K, Financial Results, SNIA Environmental Liability, Cybersecurity, Debt Repayment, Clinical Trials, Regulatory Compliance, Corporate Governance, LIVN